WO2005039556A1 - 血行再建術後の再狭窄又は再閉塞の治療及び/又は予防のための医薬 - Google Patents
血行再建術後の再狭窄又は再閉塞の治療及び/又は予防のための医薬 Download PDFInfo
- Publication number
- WO2005039556A1 WO2005039556A1 PCT/JP2004/016363 JP2004016363W WO2005039556A1 WO 2005039556 A1 WO2005039556 A1 WO 2005039556A1 JP 2004016363 W JP2004016363 W JP 2004016363W WO 2005039556 A1 WO2005039556 A1 WO 2005039556A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- restenosis
- present
- physiologically acceptable
- stent
- preventing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to a medicine for treating and / or preventing restenosis or reocclusion after revascularization, and a medical device for indwelling the blood vessel capable of preventing the restenosis or reocclusion.
- Revascularization which is mainly an intravascular interventional treatment using a catheter, which is an important treatment for vaso-occlusive disease such as angina
- restenosis of affected blood vessels after surgery occurs at a frequency of nearly 40% at most, and prevention and treatment after restenosis are problems.
- stents have been introduced in many cases after revascularization treatment, and the restenosis rate has decreased compared to before.However, restenosis appears at a frequency of about 25%, and the persistence of the effect is also a problem. It has become. Restenosis has been attributed to early thrombus formation and subsequent neointimal proliferation from pathological studies to date. Various studies have been conducted, but effective treatments have not been established yet.
- NF- ⁇ Extra factor-kappa B
- NF- ⁇ B oligo decoy can be expected to prevent restenosis after stent introduction in actual humans, it is easy to handle as a drug because it is a double-stranded oligomer of about 20 residues of nucleic acid. From the point of view, it is not always the optimal substance. In addition, from the viewpoint of synthesis cost, high cost is still required to supply a drug substance that satisfies the purity required for pharmaceuticals because purification is difficult. Therefore, the development of treatments is desired with less expensive easy low molecular handling NF-? K B inhibitors.
- An object of the present invention is to provide a medicament for treating and / or preventing restenosis or restenosis after revascularization, and a medical device for indwelling a blood vessel capable of preventing the restenosis.
- the present inventors have conducted intensive studies to solve the above-mentioned problems, and as a result, a drug containing a compound represented by the following formula or a physiologically acceptable salt thereof as an active ingredient has been reconstructed after revascularization surgery.
- the present inventors have found that the present invention can exhibit extremely high efficacy in the treatment and / or prevention of stenosis or reocclusion, and have completed the present invention.
- the present invention relates to a medicament for treating and / or preventing restenosis or restenosis after revascularization surgery, comprising a compound represented by the following formula (I) or a physiologically acceptable salt thereof:
- the present invention relates to a method for treating and / or preventing restenosis or restenosis after revascularization, which comprises treating a compound represented by the above formula (I) or a physiologically acceptable compound thereof.
- the present invention provides a method comprising treating a salt and administering a Z or prophylactically effective amount to a mammal, including a human.
- the administration is carried out by a medical device for intravascular treatment containing the compound represented by the above formula (I) or a physiologically acceptable salt thereof in a releasable form.
- a method is provided.
- the present invention provides a medical device for endovascular treatment, comprising a compound capable of releasing the compound represented by the above formula (I) or a physiologically acceptable salt thereof,
- a medical device described above which is a stent or an intravascular stent for indwelling in a blood vessel.
- This compound or a salt thereof can be easily produced by those skilled in the art.
- the kind of the salt is not particularly limited, but for example, a metal salt such as a lithium salt, a sodium salt, a potassium salt, a magnesium salt, and a calcium salt, or an ammonium salt, a methyl ammonium salt, a dimethyl ammonium salt, and a trimethyl ammonium salt And ammonium salts such as dicyclohexylammonium salt.
- a hydrate or solvate of the compound represented by the above formula (I) or a physiologically acceptable salt thereof may be used.
- the medicament of the present invention can be used as a medicament for treating and / or preventing restenosis or restenosis after revascularization surgery.
- Examples of the revascularization operation include percutaneous coronary angioplasty using an intravascular stent or an intravascular balloon catheter.
- As the active ingredient of the medicament of the present invention one or two or more substances selected from the group consisting of the above compounds and physiologically acceptable salts thereof, and hydrates and solvates thereof are mentioned. Can be used.
- the above-mentioned substance itself may be administered as the medicament of the present invention, but preferably, it can be administered as an oral or parenteral pharmaceutical composition which can be produced by a method well known to those skilled in the art.
- compositions suitable for oral administration include, for example, tablets, capsules, powders, granules, granules, solutions, and syrups.
- Pharmaceutical compositions suitable for parenteral administration include Examples thereof include injections, drops, suppositories, inhalants, transdermal absorbents, transmucosal absorbents and the like.
- the above pharmaceutical composition can be produced by adding pharmacologically and pharmaceutically acceptable additives.
- physically and pharmaceutically acceptable additives include, for example, excipients, disintegrants or disintegration aids, binders, lubricants, coatings, dyes, diluents, bases, Agents, solubilizers, tonicity agents, pH adjusters, stabilizers, propellants, and adhesives.
- the dosage of the medicament of the present invention is not particularly limited, and may be appropriately increased or decreased depending on various factors to be usually considered, such as the weight and age of the patient, the type and symptoms of the disease, and the administration route, in addition to the purpose of prevention or treatment. can do. Generally, in the case of oral administration, it can be used in the range of about 0.01 to 1,000 mg per adult day.
- the medical device provided by the present invention is a medical device used for treatment in a blood vessel in a revascularization operation, and examples thereof include an intravascular stent and an intravascular balloon catheter.
- Surgical tools such as artificial blood vessels, medical tubes, and medical clips, artificial valves, part or all of artificial hearts, and endoscopes can be mentioned.
- the material of the medical device is not particularly limited, for example, metal, plastic, polymer, biodegradable plastic, biodegradable polymer, protein, cellulose, Any material such as ceramics that is usually used for the manufacture of medical devices may be used.
- the medical device of the present invention contains a compound represented by the formula (I) or a physiologically acceptable salt thereof in a form capable of releasing into the blood, and is associated with revascularization surgery.
- the form in which the above compound or a physiologically acceptable salt thereof can be released into the blood, which can prevent and / or prevent restenosis or reocclusion of blood vessels, is not particularly limited.
- a form in which a drug prepared as a sustained-release preparation is applied or applied to the surface of the medical device can be exemplified.
- a stent for indwelling in a blood vessel is preferable, and the stent is capable of releasing a compound represented by the formula (I) or a physiologically acceptable salt thereof into blood in a sustained manner. Contained in various forms.
- the type of the base material for forming the stent is not particularly limited.
- Metal materials or polymer materials such as U S 316, S U S 304), nitinol (Ni-Ti alloy), and tantalum can be used, and biodegradable polymer materials can also be used.
- the type of the polymer material is not particularly limited as long as it has blood compatibility and does not dissolve in blood.
- the method for producing the stent of the present invention is not particularly limited.
- the surface of the stent substrate contains a compound of the above formula (I) or a physiologically acceptable salt thereof.
- a molecular coating layer can be provided.
- the stent base is a polymer material
- the compound of the above formula (I) or a physiologically acceptable salt thereof is compounded when molding the polymer material.
- a polymer coating layer containing the compound of the above formula (I) or a physiologically acceptable salt thereof can be provided on the surface of the stent substrate.
- the type of polymer forming the coating layer is blood-compatible, and the type is not particularly limited as long as it does not dissolve in blood and blood. Examples thereof include polyester-based elastomer and polyamide-based elastomer. , A polyurethane elastomer, a (meth) acrylate polymer, a polyacetate biel, and a poly (ethylene-vinyl alcohol) copolymer. Comps that can respond to stent expansion A polymeric material having a liance is more desirable.
- the concentration of the compound of the formula (I) or the physiologically acceptable salt thereof and the concentration of the polymer material in the coating solution are determined by the amount (rate) of the active ingredient eluted from the surface of the coating layer and the shape of the stain. Although it can be appropriately selected depending on the requirements such as the above, it is desirable to design the stent so as to have a sustained release property that can ensure the efficacy of the medicament of the present invention for a certain period or more. Generally, the local active ingredient concentration is ⁇ ⁇ ⁇ ! It is desirable to design it to be InM.
- stents artificial organs.
- Kamizuma on drug-eluting stents for the prevention of restenosis (Kozuma, K., Coronary Intervention, Vol. 1, pp. 58-62), and others, Catheterization and Cardiovascular Interventions, Vol. 55, pp. 409-417, 2002; New England Journal of Medicine, Vol. 346, pp. 1770-1771 and 1773-1780, 2002; W02 / 064065, etc., describe specific drug-eluting stents. I have.
- the medicine of the present invention and the medical device of the present invention may be used in combination.
- the medicament of the present invention may be administered orally or parenterally prior to revascularization, and then revascularization using the medical device of the present invention may be performed.
- the medicament of the present invention can be administered orally or parenterally during and after surgery.
- the medicament of the present invention and the method of prevention and / or treatment of the present invention include not only humans but also mammals other than humans, for example, monkeys, dogs, stags, puppies, rabbits, guinea pigs, hamsters, rats, mice, and the like. Can be targeted.
- Example 1 Neointimal inhibition test using a vascular lesion model in the femoral artery of mice
- a medicament capable of extremely effectively treating and / or preventing restenosis or reocclusion after revascularization is provided. Further, the use of the medical device of the present invention can effectively prevent restenosis or restenosis after revascularization surgery.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005515064A JPWO2005039556A1 (ja) | 2003-10-29 | 2004-10-28 | 血行再建術後の再狭窄又は再閉塞の治療及び/又は予防のための医薬 |
US10/577,487 US20070254956A1 (en) | 2003-10-29 | 2004-10-28 | Medicament for Therapeutic and/or Preventive Treatment of Restenosis or Reocclusion After Vascular Recanalization Operation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003368350 | 2003-10-29 | ||
JP2003-368350 | 2003-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005039556A1 true WO2005039556A1 (ja) | 2005-05-06 |
Family
ID=34510344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/016363 WO2005039556A1 (ja) | 2003-10-29 | 2004-10-28 | 血行再建術後の再狭窄又は再閉塞の治療及び/又は予防のための医薬 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20070254956A1 (ja) |
JP (1) | JPWO2005039556A1 (ja) |
WO (1) | WO2005039556A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2003103654A1 (ja) * | 2002-06-10 | 2005-10-06 | 株式会社医薬分子設計研究所 | NF−κB活性化阻害剤 |
US7671058B2 (en) | 2006-06-21 | 2010-03-02 | Institute Of Medicinal Molecular Design, Inc. | N-(3,4-disubstituted phenyl) salicylamide derivatives |
BR112014027983B1 (pt) | 2012-05-08 | 2022-05-24 | Aeromics, Inc | Uso de inibidores de aquaporina seletivos |
JP6083770B2 (ja) | 2013-09-13 | 2017-02-22 | 板井 昭子 | 水溶液製剤及びその製造方法 |
CN112402434A (zh) | 2013-11-06 | 2021-02-26 | 埃罗米克斯公司 | 新配方 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002049632A1 (fr) * | 2000-12-18 | 2002-06-27 | Institute Of Medicinal Molecular Design. Inc. | Inhibiteurs de production et de liberation de cytokines inflammatoires |
JP2002528420A (ja) * | 1998-10-26 | 2002-09-03 | ルードビッヒ、インスティテュート、フォー、キャンサー、リサーチ | Vegf−cまたはvegf−d遺伝子またはタンパク質を用いた再狭窄の予防 |
JP2003511110A (ja) * | 1999-10-06 | 2003-03-25 | ザ ペン ステイト リサーチ ファンデーション | 身体脈管における再狭窄を予防するシステムおよび装置 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7070964B2 (en) * | 2001-11-15 | 2006-07-04 | Kosan Biosciences Incorporated | Epothilone compounds and methods for making the same |
-
2004
- 2004-10-28 US US10/577,487 patent/US20070254956A1/en not_active Abandoned
- 2004-10-28 WO PCT/JP2004/016363 patent/WO2005039556A1/ja active Application Filing
- 2004-10-28 JP JP2005515064A patent/JPWO2005039556A1/ja not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002528420A (ja) * | 1998-10-26 | 2002-09-03 | ルードビッヒ、インスティテュート、フォー、キャンサー、リサーチ | Vegf−cまたはvegf−d遺伝子またはタンパク質を用いた再狭窄の予防 |
JP2003511110A (ja) * | 1999-10-06 | 2003-03-25 | ザ ペン ステイト リサーチ ファンデーション | 身体脈管における再狭窄を予防するシステムおよび装置 |
WO2002049632A1 (fr) * | 2000-12-18 | 2002-06-27 | Institute Of Medicinal Molecular Design. Inc. | Inhibiteurs de production et de liberation de cytokines inflammatoires |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005039556A1 (ja) | 2007-02-15 |
US20070254956A1 (en) | 2007-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3476604B2 (ja) | 薬剤を付着・コーティングしたステントの製造方法 | |
EP0588518B1 (en) | Use of 2-(3,4-dimethoxycinnamoyl)-aminobenzoic acid for the manufacture of a medicament for the treatment of restenosis | |
US20090253796A1 (en) | Method for treating vascular disease | |
CN101557814A (zh) | 大环内酯化合物及它们的使用方法 | |
JP6387359B2 (ja) | ラパマイシン誘導体を含む埋め込み型医療用デバイスの製造方法 | |
KR20080073328A (ko) | 약제 방출 제어 조성물 및 약제 방출성 의료 기구 | |
JP2010501229A (ja) | メラトニンとパクリタキセルとの組合せを備えた医療用ステント | |
CN101130115A (zh) | 利用c-jun n端激酶抑制剂的药物释放支架及其治疗方法 | |
US20090222080A1 (en) | Medical stent provided with inhibitors of tumor necrosis factor-alpha | |
WO2005039556A1 (ja) | 血行再建術後の再狭窄又は再閉塞の治療及び/又は予防のための医薬 | |
KR20050119665A (ko) | 재발협착증을 예방하기 위한 장치, 방법 및 조성물 | |
JP2016523588A (ja) | 治療剤配合物が充填されている中空ステント | |
CA2490811A1 (en) | Use of organic compounds | |
WO2006115279A1 (ja) | 血管内皮温存化組成物 | |
JP4955392B2 (ja) | 血管内膜過増殖疾患の予防または治療剤 | |
US7229979B2 (en) | Hypoestoxides, derivatives and agonists thereof for use as stent-coating agents | |
US5416120A (en) | Vascular hypertrophy inhibitor | |
US20070196418A1 (en) | Drug delivery methods and devices | |
JP2002193838A (ja) | 体内埋め込み医療材料および体内埋め込み医療器具 | |
MXPA01007833A (es) | Metodo para prevenir o reducir eventos cardiovasculares asociados con intervencion de la arteria coronaria. | |
JP2006506336A (ja) | 動静脈の移植不全の予防及び/または処置のためのキマーゼ阻害剤の使用 | |
JP2003267876A (ja) | 新規な血管狭窄治療剤又は予防剤 | |
JP2005289818A (ja) | 動脈硬化抑制剤および治療剤 | |
WO2000045811A1 (en) | Method for the prevention or reduction of cariovascular events associated with coronary intervention |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005515064 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10577487 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase | ||
WWP | Wipo information: published in national office |
Ref document number: 10577487 Country of ref document: US |